Jul 05, 2022
AbbVie: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients With Refractory, Moderate to Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled With Other Systemic Drug Products
Thursday, July 21
The goals of this program are to understand the burden of AD, to discuss the efficacy and safety of RINVOQ in patients with moderate to severe AD, and to review resources available through RINVOQ Complete.
When: Thursday, July 21 | 7 p.m. Registration and Meal | 7:30 p.m. Program
Where: Room 118/119 | Vancouver Convention Centre
